Michel Vounatsos (Credit: World Economic Forum/Valeriano Di Domenico)

March 8, 2022 09:44 AM ESTUpdated March 11, 02:56 AM

‘We would have no choice’: Biogen CEO Vounatsos isn’t about to let go of the budget axe — unless they break that losing streak

Biogen CEO Michel Vounatsos is betting on success. But he’s keeping one hand firmly on the budget axe in case the cards stay cold. And …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE LOG IN

ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Lilly shuffles key executive positions; Mikael Dolsten takes another post-Pfizer assignment

Corvus' early-phase atopic dermatitis data prompt stock rally

'Find a way, or make one': How two scientists hope to revitalize CRISPR's rare disease crisis

AI biotech Insilico Medicine goes for third attempt at Hong Kong IPO

GSK awaits Nucala decision after FDA target date passes

sponsored

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges